Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Neoplasm
Interventions: DRUG: Pembrolizumab
Sponsor: Universitaire Ziekenhuizen KU Leuven